Alpha Cognition (ACOG) Income from Continuing Operations (2023 - 2026)
Alpha Cognition (ACOG) posted quarterly Income from Continuing Operations of 7925270.0 for Q4 2025, down 211.22% year-over-year from 7125517.55 in Q4 2024, and down 701.28% quarter-over-quarter from 1318074.0 in Q3 2025.
Alpha Cognition (ACOG) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Alpha Cognition's Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 7925270.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 211.22% year-over-year to 7925270.0; the TTM figure through Dec 2025 stood at 21812967.0 (down 89.27% YoY), while the FY2025 annual figure was 42551689.0, down 51.69% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 7925270.0, down from 1318074.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1318074.0 in Q3 2025, with the low at 13199228.0 in Q2 2025.
- The 3-year median for Income from Continuing Operations is 2546486.0 (2024), against an average of 3747239.73.
- Peak annual rise in Income from Continuing Operations reached 170.87% in 2025, while the deepest fall reached 523.93% in 2025.
- Alpha Cognition's Income from Continuing Operations stood at 2381831.0 in 2023, then retreated by 6.91% to 2546486.0 in 2024, then plunged by 211.22% to 7925270.0 in 2025.
- Business Quant data shows ACOG's Income from Continuing Operations at 7925270.0 in Q4 2025, 1318074.0 in Q3 2025, and 13199228.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Alpha Cognition | 219.48 Mn | 178.04 Mn | 5.70 Mn | -7.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.01 Mn |
| Dec 31, 2025 | -7.93 Mn |
| Sep 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | -13.20 Mn |
| Mar 31, 2025 | -2.01 Mn |
| Dec 31, 2024 | -2.55 Mn |
| Sep 30, 2024 | -1.86 Mn |
| Jun 30, 2024 | -2.12 Mn |
| Mar 31, 2024 | -5.00 Mn |
| Dec 31, 2023 | -2.38 Mn |
| Sep 30, 2023 | -2.77 Mn |
| Jun 30, 2023 | -2.73 Mn |